Get the Stockscreener App
76.08
3.30%
2.43
Nuvalent Inc stock is traded at $76.08, with a volume of 391.80K.
It is up +3.30% in the last 24 hours and down -5.70% over the past month.
Nuvalent Inc is a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer. All of the Company's operations are in the United States. The company is engaged in developing small molecules that are designed to overcome the limitations of existing therapies for clinically validated kinase targets. The product candidates of the company include NVL-520, which is being developed for patients with ROS1-positive non-small cell lung cancer (NSCLC), NVL-655, which is being developed for patients with anaplastic lymphoma kinase (ALK)-positive NSCLC, NVL-330, is a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to address the combined medical need of treating tumors driven by HER2ex20.
See More
Previous Close:
$73.65
Open:
$74.48
24h Volume:
391.80K
Relative Volume:
0.80
Market Cap:
$5.07B
Revenue:
-
Net Income/Loss:
$-224.29M
P/E Ratio:
-19.51
EPS:
-3.9
Net Cash Flow:
$-185.06M
1W Performance:
+0.05%
1M Performance:
-5.70%
6M Performance:
-4.29%
1Y Performance:
-8.34%
1-Day Range:
$73.68
$76.44
1-Week Range:
$71.68
$78.00
52-Week Range:
$55.53
$113.51
Nuvalent Inc Stock (NUVL) Company Profile
Name
Nuvalent Inc
Sector
Industry
Phone
508-446-2272
Address
ONE BROADWAY, 14TH FLOOR, CAMBRIDGE
Compare NUVL with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NUVL
Nuvalent Inc
|
76.08 | 5.41B | 0 | -224.29M | -185.06M | -3.90 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.12 | 99.96B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
589.48 | 60.83B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
454.38 | 59.89B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
660.00 | 40.47B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
313.67 | 37.96B | 3.81B | -644.79M | -669.77M | -6.24 |
Nuvalent Inc Stock (NUVL) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-14-25 | Upgrade | UBS | Neutral → Buy |
| Dec-30-24 | Initiated | H.C. Wainwright | Buy |
| Oct-24-24 | Initiated | UBS | Neutral |
| Aug-29-24 | Initiated | Barclays | Overweight |
| Apr-17-24 | Initiated | Jefferies | Buy |
| Apr-01-24 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Feb-28-24 | Resumed | Guggenheim | Buy |
| Feb-23-24 | Initiated | Robert W. Baird | Outperform |
| Sep-27-23 | Initiated | Stifel | Buy |
| Aug-08-23 | Initiated | SVB Securities | Market Perform |
| Jul-24-23 | Initiated | Guggenheim | Buy |
| Jan-18-23 | Initiated | Wedbush | Outperform |
| Jun-24-22 | Initiated | BMO Capital Markets | Outperform |
View All
Nuvalent Inc Stock (NUVL) Latest News
Regression Model Predicts Rangebound Movement in Nuvalent Inc.2025 Pullback Review & Momentum Based Trading Signals - classian.co.kr
Nuvalent Announces Positive Pivotal Data for Zidesamtinib in Lung Cancer - MSN
Piper Sandler initiates coverage of oncology companies (CGON:NASDAQ) - Seeking Alpha
Piper Sandler initiates Nuvalent stock coverage with Overweight rating - Investing.com
Is Nuvalent Inc. showing insider buying2025 EndofYear Setup & Stepwise Entry and Exit Trade Signals - newsimpact.co.kr
Nuvalent Inc. Hits Oversold Level on RSI Indicator2025 Key Highlights & Real-Time Sentiment Analysis - metal.it
Is Nuvalent Inc. stock a buy or sellJuly 2025 Weekly Recap & Community Driven Trade Alerts - mustnews.co.kr
Is Nuvalent Inc. in a bullish channel2025 Bull vs Bear & Stepwise Entry/Exit Trade Alerts - thegnnews.com
Heatmap Data Shows High Activity in Nuvalent Inc. Sector2025 Price Action Summary & Daily Stock Trend Reports - 선데이타임즈
Is Nuvalent Inc. stock overvalued or fairly pricedTrade Exit Summary & Free AI Powered Buy and Sell Recommendations - classian.co.kr
Nuvalent’s SWOT analysis: oncology innovator’s stock faces pivotal year By Investing.com - Investing.com Nigeria
Nuvalent’s SWOT analysis: oncology innovator’s stock faces pivotal year - Investing.com
Inhibrx Awaits Ozekibart Clinical Data in October - AInvest
Nuvalent to Present Pivotal Data from ARROS-1 Clinical Trial of Zidesamtinib for TKI Pre-treated Patients with Advanced ROS1-positive NSCLC at WCLC 2025 Presidential Symposium - The Malaysian Reserve
Nuvalent to present pivotal lung cancer drug data at WCLC 2025 - Investing.com Nigeria
J.P. Morgan Analyst Keeps Buy Rating on Nuvalent with $111 Price Target - AInvest
How Nuvalent Inc. stock performs during market volatilityTop Fast Growth Opportunities - thegnnews.com
Can Nuvalent Inc. navigate macro headwindsWeekly Investment Watchlist - sisain.net
Quant Strategy Flags Nuvalent Inc. for EntryShort Term Buy Zone Stock Alerts Signal Entry - metal.it
Nuvalent Reports Q2 2025 Financials and Pipeline Progress - TipRanks
Nuvalent’s Promising Developments and Strong Financial Position Justify Buy Rating - TipRanks
Nuvalent’s Promising Drug Pipeline and Strategic Trials Drive Buy Rating - TipRanks
Nuvalent Reports Q2 2025 Financial Results and Highlights Pipeline Progress - AInvest
Nuvalent's Q2 Net Loss Widens - MarketScreener
Nuvalent's 2025 Momentum: Catalysts, Commercial Readiness, and Cash Runway Positioning for a Breakout Year - AInvest
Nuvalent (NUVL) Q2 R&D Up 65% - The Motley Fool
Nuvalent initiates rolling NDA submission for ROS1-positive NSCLC drug By Investing.com - Investing.com Australia
Nuvalent initiates rolling NDA submission for ROS1-positive NSCLC drug - Investing.com India
Earnings Flash (NUVL) Nuvalent Posts Q2 Net Loss Per Share $1.39, vs. FactSet Est of $1.22 - MarketScreener
Nuvalent, Inc. SEC 10-Q Report - TradingView
Nuvalent Highlights Pipeline and Business Achievements, Reiterates Key Anticipated Milestones, and Reports Second Quarter 2025 Financial Results - MarketScreener
Nuvalent's Dual Victory: FDA Rolling Review for ROS1 Cancer Drug While Phase 3 Trial Advances New ALK Treatment - Stock Titan
Analysts' Bullish Sentiments on Healthcare Companies: Avantor, Nuvalent, and Alphatec Holdings - AInvest
Analysts Offer Insights on Healthcare Companies: Avantor (AVTR), Nuvalent (NUVL) and Alphatec Holdings (ATEC) - The Globe and Mail
What catalysts could drive Nuvalent Inc. stock higher in 2025Build wealth faster with consistent growth stocks - Jammu Links News
What makes Nuvalent Inc. stock price move sharplyInvest confidently with professional market insights - Jammu Links News
Is Nuvalent Inc. a growth stock or a value stockExceptional financial outcomes - Jammu Links News
How volatile is Nuvalent Inc. stock compared to the marketInvest confidently with real-time data - Jammu Links News
What is the dividend policy of Nuvalent Inc. stockDynamic investment growth - Jammu Links News
How many analysts rate Nuvalent Inc. as a “Buy”Achieve breakthrough investment performance - Jammu Links News
What institutional investors are buying Nuvalent Inc. stockFind the best stocks for sustainable growth - Jammu Links News
What is the risk reward ratio of investing in Nuvalent Inc. stockGet ahead with breakthrough trading ideas - Jammu Links News
Published on: 2025-08-03 06:27:04 - Jammu Links News
Nuvalent’s Noci sells $321k in shares By Investing.com - Investing.com Australia
Nuvalent’s Noci sells $321k in shares - Investing.com India
Nuvalent Inc Stock (NUVL) Financials Data
Revenue
Net Income
Cash Flow
EPS
Nuvalent Inc Stock (NUVL) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Porter James Richard | President and CEO |
Aug 15 '25 |
Sale |
75.42 |
27,000 |
2,036,325 |
249,062 |
| Pelish Henry E. | Chief Scientific Officer |
Aug 07 '25 |
Option Exercise |
27.71 |
5,500 |
152,415 |
66,456 |
| Pelish Henry E. | Chief Scientific Officer |
Aug 07 '25 |
Sale |
74.85 |
5,500 |
411,675 |
60,956 |
| Noci Darlene | Chief Development Officer |
Jul 30 '25 |
Option Exercise |
27.85 |
4,000 |
111,400 |
52,034 |
| Noci Darlene | Chief Development Officer |
Jul 30 '25 |
Sale |
80.36 |
4,000 |
321,440 |
48,034 |
0.94%
1.72%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):